

ARTICLE

Open Access

# Aberrant development of pancreatic beta cells derived from human iPSCs with *FOXA2* deficiency

Ahmed K. Elsayed<sup>1</sup>, Ihab Younis<sup>2</sup>, Gowher Ali<sup>1</sup>, Khalid Hussain<sup>3</sup> and Essam M. Abdelalim<sup>1,4</sup>

## Abstract

*FOXA2* has been identified as an essential factor for pancreas development and emerging evidence supports an association between *FOXA2* and diabetes. Although the role of *FOXA2* during pancreatic development is well-studied in animal models, its role during human islet cell development remains unclear. Here, we generated induced pluripotent stem cells (iPSCs) from a patient with *FOXA2* haploinsufficiency (*FOXA2*<sup>+/-</sup> iPSCs) followed by beta-cell differentiation to understand the role of *FOXA2* during pancreatic beta-cell development. Our results showed that *FOXA2* haploinsufficiency resulted in aberrant expression of genes essential for the differentiation and proper functioning of beta cells. At pancreatic progenitor (PP2) and endocrine progenitor (EPs) stages, transcriptome analysis showed downregulation in genes associated with pancreatic development and diabetes and upregulation in genes associated with nervous system development and WNT signaling pathway. Knockout of *FOXA2* in control iPSCs (*FOXA2*<sup>-/-</sup> iPSCs) led to severe phenotypes in EPs and beta-cell stages. The expression of *NGN3* and its downstream targets at EPs as well as *INSULIN* and *GLUCAGON* at the beta-cell stage, were almost absent in the cells derived from *FOXA2*<sup>-/-</sup> iPSCs. These findings indicate that *FOXA2* is crucial for human pancreatic endocrine development and its defect may lead to diabetes based on *FOXA2* dosage.

## Introduction

During human development, early endodermal tissue becomes specified toward a pancreatic fate before evagination of pancreatic buds, populated with pancreatic progenitors. All adult pancreatic cells are originated from the same progenitors expressing a group of transcription factors (TFs), including *PDX1*, *SOX9*, *FOXA2*, *NKX6.1*, *HNF6*, and *PTF1A*<sup>1,2</sup>. Monogenic diabetes (MD) is caused by a mutation or defect in a single gene-regulating beta-cell development and/or function<sup>3</sup>. Several heterozygous mutations in the TFs expressed during pancreatic development are associated with a specific form of MD, known as MODY. However, homozygous mutations of the same

TFs lead to neonatal diabetes, which can be associated with pancreatic hypoplasia/agenesis in some mutations<sup>4</sup>. This indicates that the onset and severity of the diabetes phenotype are correlated with the dosage of the TF expression during pancreatic development.

*FOXA2* is expressed in several tissues and performs distinct functions as evident in the phenotypes of mouse models<sup>5</sup>. *Foxa2* knockout mice die at an early embryonic stage and show developmental defects in the foregut (FG) and neural tube<sup>6-8</sup>. During pancreatic development, *FOXA2* is expressed at early stages starting from the endoderm stage and its protein level is increased during the endocrine specification stage<sup>1,9</sup>, while the exocrine and ductal cells express a low level of *FOXA2*<sup>9</sup>. Mouse studies showed that *Foxa2* is important for islet development and beta-cell functionality<sup>6,10-12</sup> and its specific deletion in beta-cells leads to hyperinsulinemic hypoglycemic phenotype<sup>13,14</sup>. In human, previous reports demonstrated that patients with heterozygous *FOXA2* mutations develop hyperinsulinemia, hypoglycemia,

Correspondence: Essam M. Abdelalim (emohamed@hbku.edu.qa)


<sup>1</sup>Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar

<sup>2</sup>Biological Sciences Program, Carnegie Mellon University, Qatar Foundation, Education City, Doha, Qatar

Full list of author information is available at the end of the article

Edited by A. Finazzi-Agrò

© The Author(s) 2021, corrected publication 2021

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

hypopituitarism, endodermal organ defects, and craniofacial abnormalities<sup>15,16</sup>. Recent genomic studies found that type 2 diabetes (T2D) risk alleles are associated with FOXA2-bound enhancers in human<sup>17</sup>. Another recent study reported a patient with diabetes due to a heterozygous missense variant in *FOXA2*, indicating that FOXA2 defect can lead to MD<sup>18</sup>. FOXA2 is known to regulate the expression of multiple TFs controlling pancreatic endocrine cell fate and insulin secretion<sup>19,20</sup>.

Most of the information available on FOXA2 functions have been obtained from animal studies<sup>7,10,11,13,21</sup>, which do not fully reflect human phenotypes. Recent progress in the induced pluripotent stem cell (iPSC) technology allowed us to generate in vitro models to study human genetic diseases<sup>22</sup>. To our knowledge, there is only one recent study that used *FOXA2* knockout hESCs (FOXA2<sup>-/-</sup> hESCs) to study FOXA2 during pancreatic progenitor differentiation<sup>23</sup>. To better understand the role of FOXA2 in beta cell development and diabetes progression, we established iPSCs from a patient with a heterozygous deletion in *FOXA2* (FOXA2<sup>+/-</sup> iPSCs)<sup>24</sup>. We showed a number of key genes essential for pancreatic development were dysregulated in FOXA2<sup>+/-</sup> iPSC-derived pancreatic cells and the results obtained were further validated by generating CRISPR/Cas9-mediated FOXA2 knockout (FOXA2<sup>-/-</sup> iPSCs). Our results suggest that FOXA2 have a crucial role in pancreatic endocrine development in human.

## Results

### Derivation of iPSCs from a patient with FOXA2 heterozygous deletion

Recently, we reported the generation of an iPSC line from a patient with a heterozygous deletion in *FOXA2* gene (QBRIi009-A; FOXA2<sup>+/-</sup> iPSC-C1)<sup>24</sup> and from a healthy control (QBRIi001; Ctr1-iPSCs)<sup>25</sup>. In this study, we generated additional iPSC lines from another healthy control (Ctr2-iPSCs). All the established iPSC lines showed the expression of the pluripotency markers and showed the ability to differentiate into the three germ layers (Supplementary Figs. S1 and S2). Ctr-iPSC lines showed normal karyotype, while FOXA2<sup>+/-</sup> iPSC lines showed a translocation between the short arm of chromosome 6 and 20, karyotype: [46 XY, t (6; 20) (p11; p11)] and a deletion [46, XY, del (20) (p11.21p11.22)] as expected<sup>24</sup> and as reported in the patient sample<sup>26</sup> (Supplementary Fig. S1E). Three well-characterized clones from FOXA2<sup>+/-</sup> iPSCs were utilized for the subsequent experiments.

### Effect of FOXA2 haploinsufficiency on definitive endoderm (DE) formation


To investigate the effect of *FOXA2* heterozygous deletion on pancreatic beta-cell development, Ctr-iPSCs and

three FOXA2<sup>+/-</sup> iPSC lines were differentiated into all stages of beta cells as previously reported<sup>27–29</sup> (Supplementary Fig. S3A). Since FOXA2 expression starts at the definitive endoderm (DE) stage, we examined the impact of *FOXA2* haploinsufficiency on DE formation. The protein and mRNA levels of FOXA2 were significantly reduced in DE derived from the three FOXA2<sup>+/-</sup> iPSC lines in comparison to those derived from Ctr-iPSC lines (Fig. 1A–D), confirming *FOXA2* haploinsufficiency. qPCR analysis showed a significant decrease in the expression of SOX17, the DE marker (Fig. 1B). Furthermore, immunostaining and flow cytometry analyses showed a marked reduction in the expression of the DE markers, SOX17 and FOXA2 and a significant increase in the expression of the pluripotency markers, OCT4 and SOX2 in the DE derived from the FOXA2<sup>+/-</sup> iPSC lines compared to those derived from Ctr-iPSCs (Fig. 1C, D). OCT4<sup>+</sup> cells ranged from 35 to 51% in the DE derived from FOXA2<sup>+/-</sup> iPSCs compared to 5–9% in those derived from Ctr-iPSCs (Fig. 1D) indicating the retention of the pluripotency markers and a delay in DE formation as a result of *FOXA2* deficiency.


### FOXA2 deficiency leads to aberrant development of PDX1<sup>+</sup>/NKX6.1<sup>+</sup> progenitors and endocrine progenitors

We next sought to assess the impact of *FOXA2* deficiency on the differentiation of pancreatic progenitors (PP2) and endocrine progenitors (EPs). FOXA2 protein and mRNA levels were markedly reduced in PP2 derived from FOXA2<sup>+/-</sup> iPSCs (Fig. 2A, B), confirming the haploinsufficiency. We noticed that the efficiency of PP2 was negatively impacted as a result of FOXA2 reduction. The immunostaining and flow cytometry analyses showed a significant decrease in the expression of the key pancreatic progenitor TFs, PDX1 and NKX6.1 (above 35% reduction in PDX1 and NKX6.1) (Fig. 2C–E), further confirmed at mRNA levels using qPCR (Fig. 2F). The co-expression of PDX1 and NKX6.1 in the PP2 is known to be the origin of pancreatic beta cells<sup>27,28</sup>. Furthermore, we investigated the mRNA expression levels of other TFs, expressed at the PP2 stage and are important for beta-cell development, including *SOX9*, *GATA6*, *ONECUT1* (*HNF6*), *HNF1A*, and *PAX4* as well as the exocrine precursor markers, *PTF1A* and *AMYLASE*. Interestingly, all these pancreatic markers were significantly down-regulated in PP2 derived from FOXA2<sup>+/-</sup> iPSC lines compared to those derived from Ctr-iPSCs (Fig. 2F), indicating the importance of FOXA2 in PP2.

To investigate the effect of *FOXA2* deficiency on EPs, the PP2 were further differentiated into EPs. The down-regulation of FOXA2 was confirmed at the end of stage 5 (Fig. 3A, B). The immunostaining showed a decrease in the expression of the endocrine marker, chromogranin A (CHGA), as a result of FOXA2 deficiency (Fig. 3A). Also,








**Fig. 2** Effect of FOXA2 haploinsufficiency on pancreatic progenitor (PP2) differentiation. Western blotting (A) and qPCR analysis (B) for FOXA2 protein and mRNA expression levels in iPSC-derived PP2. C Representative immunofluorescent images showing the expression of PDX1 and NKX6.1 in the PP2 derived from Ctr-iPSCs and FOXA2<sup>+/-</sup> iPSCs. D Flow cytometry histograms showing the expression of PDX1 and NKX6.1 in the PP2 derived from Ctr-iPSCs and FOXA2<sup>+/-</sup> iPSCs. E Quantification of the expression of PDX1 and NKX6.1 shown in D. F qPCR quantification for the expression of key PP2 markers, PDX1, NKX6.1, SOX9, HNF1A, GATA6, PAX4, ONECUT1 (HNF6), PTF1A, and AMYLASE in the generated PP2. Data are represented as mean  $\pm$  SD; \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.





**Fig. 3 Effect of FOXA2 haploinsufficiency on pancreatic endocrine progenitors (EPs) differentiation.** **A** Representative immunofluorescent images showing the expression of FOXA2, NGN3, CHGA, NEUROD1, and NKX6.1 in endocrine progenitors (EPs) derived from Ctr-iPSCs and FOXA2<sup>+/-</sup> iPSCs. **B** Real-time PCR analysis for the expression of the key EPs markers, FOXA2, NGN3, CHGA, NEUROD1, NKX6.1, and NKX2.2 in the EPs derived from Ctr-iPSCs and FOXA2<sup>+/-</sup> iPSCs. Data are represented as mean ± SD; \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.

the expression levels of NEUROGENIN 3 (NGN3), a crucial TF for endocrine specification, and its downstream targets, NEUROD1 and NKX2.2, as well as NKX6.1, were markedly reduced in the EPs derived from FOXA2<sup>+/-</sup> iPSCs compared to those generated from Ctr-iPSCs as indicated by immunostaining and qPCR (Fig. 3A, B). Furthermore, we examined the effect of FOXA2 deficiency on FOXA1 expression at PP2 and EPs. We found that FOXA2 deficiency resulted in a significant reduction in the FOXA1 mRNA levels (Supplementary Fig. S3B), suggesting a lack of a compensatory mechanism.

#### Transcriptomic alterations in PP2 and EPs derived from FOXA2<sup>+/-</sup> iPSCs

To gain further insight into the gene regulatory network influenced by FOXA2 leading to progenitor development defects, we performed whole-transcriptome profiling using RNA-Seq analysis on PP2 and EPs. Our transcriptome analysis identified 610 downregulated (Log2 FC < -1.0,  $p < 0.05$ ) and 427 upregulated (Log2 FC > 1.0,  $p < 0.05$ ) differentially expressed genes (DEGs) in PP2 derived from FOXA2<sup>+/-</sup> iPSCs compared to those generated from Ctr-iPSCs (Fig. 4A). To investigate biological functions and pathways enriched in FOXA2-deficient PP2, GO and KEGG pathway enrichment analyses were performed. The enriched pathways of the downregulated DEGs were mainly associated with pancreatic development, liver development, glucose homeostasis, insulin secretion, MODY, T2D, and NOTCH signaling (Fig. 4B, C and Supplementary Table S4). However, the upregulated DEGs led to several enriched pathways, such as axon guidance, nervous system development, and WNT and BMP signaling (Fig. 4B, C and Supplementary Fig. S3C, Supplementary Table S5). Consistent with the qPCR results in Fig. 2F, the main PP2-specific TFs were significantly downregulated, such as *PDX1*, *NKX6.1*, *FOXA2*, *SOX9*, *GATA6*, *PAX4*, *HNF6*, and *PTF1A* (Figs. 2F, 4C and Supplementary Table S4). Furthermore, several genes involved in the endocrine specification and diabetes development were significantly downregulated, such as *HES1*, *INSM1*, *HNF1A*, *NEUROD1*, *NGN3*, *NKX2.2*, *GIPR*, *MNX1*, *PROX1*, *TCF7L2*, and *HHEX* (Fig. 4C and Supplementary Table S4). Consistent with pancreatic developmental defects, we noticed a significant reduction in the genes involved in the NOTCH signaling pathway, such as *SOX9*, *NOTCH1*, *HES1*, and *HEY1*, which have a key role in PP2 differentiation (Fig. 4C and Supplementary Table S4).

To validate the RNA-Seq data, we examined the mRNA expression levels of selected DEGs. qPCR showed a significant reduction in *NEUROD1*, *TCF7L2*, *INSR*, *NOTCH1*, *HES1*, *MNX1*, *ISL1*, *PROX1*, *PTPRN*, *ADRA2A*, and *CDX2* (Fig. 4D). Furthermore, the results showed a significant upregulation in *BMP4*, *NOGGIN*, *MSX1*,

*MSX2*, *DKK1*, *DLX2*, *DLX5*, *EMX2*, *ERG2*, *OTX1*, *OTX2*, *SOX2*, and *PAX6* (Fig. 4E). These results are consistent with the RNA-Seq data.


Our RNA-Seq analysis on EPs identified 643 downregulated (Log2 FC < -1.0,  $p < 0.05$ ) and 564 upregulated (Log2 FC > 1.0,  $p < 0.05$ ) DEGs in EPs derived from FOXA2<sup>+/-</sup> iPSCs compared to those generated from Ctr-iPSCs (Fig. 5A). The enriched pathways of the downregulated and upregulated DEGs were similar to those observed in PP2 (Fig. 5B). The downregulated DEGs were mainly associated with endocrine pancreas development, NOTCH signaling pathway, MODY, and insulin secretion and glucose homeostasis (Fig. 5B, C and Supplementary Table S6). However, the upregulated DEGs were mainly associated with neurogenesis and nervous system development, WNT pathway, and BMP signaling pathway (Fig. 5B, C and Supplementary Fig. S3D, Supplementary Table S7). In addition to the downregulated pancreatic endocrine TFs shown in Fig. 3B, we further validated selected upregulated DEGs using qPCR. Consistent with RNA-Seq data, the mRNA levels of *DLX5*, *EMX2*, *OTX1*, *OTX2*, *BMP4*, *NOGGIN*, and *SIX4* were significantly upregulated in the EPs derived from FOXA2<sup>+/-</sup> iPSCs compared to those derived from Ctr-iPSCs (Fig. 5D).

#### Effect of FOXA2 haploinsufficiency on beta-cell differentiation


In order to investigate the influence of FOXA2 haploinsufficiency on beta cells, the EPs were further differentiated into beta cells. Ctr-iPSCs and FOXA2<sup>+/-</sup> iPSCs were able to generate INSULIN (INS)<sup>+</sup> cells. However, the expression levels of INS, NKX6.1, C-PEP, and GLUCAGON (GCG) were downregulated as examined by immunostaining and flow cytometry in stage 7 derived from FOXA2<sup>+/-</sup> iPSCs compared to those derived from Ctr-iPSCs (Fig. 6A–C). The expression of NKX6.1 in INS<sup>+</sup> cells, one of the hallmarks of the functionality of beta cells, was also reduced. Furthermore, the mRNA levels of *ABCC8*, *KCNJ11*, *NKX2.2*, and *PDX1*, which are known to be regulated by FOXA2<sup>19,20</sup> were significantly downregulated due to FOXA2 haploinsufficiency (Fig. 6D). These results indicate that the number of beta and alpha cells are reduced as a result of FOXA2 haploinsufficiency.

To test the functionality of the generated beta cells, we performed a GSIS assay. The ability of iPSC-derived beta-cell aggregates to secrete C-PEP in response to low (2.8 mM) and high (20 mM) glucose and KCl stimulation was measured. Beta cells derived from FOXA2<sup>+/-</sup> iPSCs and Ctr-iPSCs showed a significant increase in the secreted C-PEP in response to high glucose (FC > 3.0) and KCl stimulation compared to low glucose levels (Fig. 6E, F). We did not notice a significant difference in glucose responsiveness between the beta cells derived from










FOXA2<sup>+/-</sup> iPSCs and those derived from Ctr-iPSCs (Fig. 6E). However, KCl stimulation showed a significant reduction in the C-PEP content in beta cells derived from FOXA2<sup>+/-</sup> iPSCs compared with those derived from Ctr-

iPSCs (Fig. 6E). These results indicate that FOXA2-deficient beta cells are functional, but the total content of insulin is reduced as a result of a lower number of beta cells due to FOXA2 haploinsufficiency.



### FOXA2 knockout in iPSCs impairs endocrine pancreatic development

To confirm the results obtained from the FOXA2<sup>+/-</sup> iPSCs and to exclude the possibility of cell line variations,

we used CRISPR/Cas9 to KO the FOXA2 gene in the iPSCs (FOXA2<sup>-/-</sup> iPSCs) (Supplementary Fig. S4A–D). We generated FOXA2<sup>-/-</sup> iPSCs from Ctr1-iPSCs and Ctr2-iPSCs used in the current study and compared them

with isogenic  $FOXA2^{+/+}$  wild type (WT) controls. Characterization of both  $FOXA2^{-/-}$  iPSC lines showed that they were pluripotent and displayed normal karyotype (Supplementary Fig. S4E). Next,  $FOXA2^{-/-}$  iPSC lines and their WT controls were differentiated into beta cells. Western blotting showed that the FOXA2 protein was completely lost in the DE and PP2 derived from  $FOXA2^{-/-}$  iPSC lines (Fig. 7A, B). Consistent with the results obtained from  $FOXA2$  haploinsufficiency, the expression of the key TFs, PDX1 and NKX6.1 were markedly reduced in PP2 derived from  $FOXA2^{-/-}$  iPSC lines compared to WT iPSCs as examined by immunostaining (Fig. 7C). At the EPs stage, the immunostaining analysis showed that the depletion of FOXA2 resulted in the generation of a very low number of  $NGN3^+/NKX2.2^+$  cells in comparison to WT controls (Fig. 7D). Furthermore, qPCR results showed a highly significant reduction in the expression of the main endocrine TFs, *NGN3*, *NEUROD1*, and *NKX2.2* in the EPs derived from  $FOXA2^{-/-}$  iPSC lines (Fig. 7E). Interestingly, immunostaining showed that only a small number of  $INS^+$  and  $GCG^+$  cells were detected in  $FOXA2^{-/-}$  iPSC-derived beta cells compared to WT (Fig. 7F). Consistent with these findings, qPCR showed significant downregulation in the endocrine and beta-cell genes, *NEUROD1*, *NKX2.2*, *INS*, *GCG*, *ABCC8*, *KCJ11*, *PDX1*, and *HHEX1* (Fig. 7G). Our results showed that the  $FOXA2^{-/-}$  phenotypes were more severe than those obtained from  $FOXA2^{+/-}$  iPSCs indicating that FOXA2 is required for endocrine pancreatic development.

#### Overexpression of FOXA2 in pancreatic progenitors reverses the phenotype associated with FOXA2 deficiency

In order to examine whether the phenotype observed due to  $FOXA2$  deficiency can be reversed by re-introducing FOXA2 expression, we overexpressed FOXA2 at day 2 of stage 4 of differentiation (PP2 stage) derived from  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs (Fig. 8A). qPCR analysis at the end of stage 4 showed that FOXA2 OE resulted in a significant increase in the expression of the genes that were downregulated in  $FOXA2$ -deficient PP2 cells (Fig. 8B). Furthermore, FOXA2 OE led to a significant downregulation in the majority of the genes that were upregulated in  $FOXA2$ -deficient PP2 cells (Fig. 8C).

In order to assess the effect of the transient FOXA2 OE at the PP2 stage on iPSC differentiation towards pancreatic beta cells, we evaluated the key beta-cell markers and GSIS in stage 7 cells derived from both  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs after FOXA2 overexpression. At stage 7, we found that FOXA2 OE at PP2 resulted in a significant increase in the expression of the key pancreatic endocrine genes, including *INS*, *GCG*, *SST*, *PDX1*, *NKX6.1*, *ABCC8*, *KCNJ11*, *HHEX*, and *NEUROD1* in

comparison to those transfected with the empty vector (Fig. 8D). Consistent with these findings, the immunostaining results showed an increase in the number of  $INS^+$  and  $GCG^+$  cells derived from  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs after FOXA2 OE (Fig. 8E). Since the total content of insulin was reduced in beta cells derived from  $FOXA2^{+/-}$  iPSCs (Fig. 6E), we examined the effect of FOXA2 OE on the C-PEP content. KCl stimulation showed a significant increase in the C-PEP content in beta cells derived from  $FOXA2^{+/-}$  iPSCs overexpressed with FOXA2 compared with those transfected with the empty vector (Fig. 8E). These results indicate that FOXA2 OE can reverse the phenotype observed in the  $FOXA2$ -deficient pancreatic cells.


#### Effect of PDX1 overexpression on FOXA2-deficient pancreatic progenitors


Previous studies reported that FOXA2 controls the *PDX1* gene during pancreatic beta-cell development in rodents and humans<sup>10,12,30</sup>. Therefore, we thought to examine the effect of PDX1 overexpression (PDX1 OE) at the PP2 stage on reversing the phenotype associated with  $FOXA2$  deficiency (Supplementary Fig. S5A, B). As expected, PDX1 OE led to an increase in the mRNA expression levels of several key PP2 genes that were downregulated in  $FOXA2$ -deficient PP2 derived from  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs, such as *NKX6.1*, *GATA6*, *PAX4*, *PTF1A*, *AMYLASE*, *TCF7L2*, *INSR*, *HES1*, *MNX1*, *PROX1*, *PTPRN1*, and *ADRA2A* (Supplementary Fig. S5C, D). Furthermore, PDX1 OE led to a downregulation in the expression of some genes that were upregulated in the  $FOXA2$ -deficient PP2 derived from  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs, such as *ERG2*, *OTX1*, and *OTX2* (Supplementary Fig. S5C, D). On the other hand, some genes were not significantly changed as a result of PDX1 OE, such as *SOX9*, *ONECUT1*, *NOG*, *DKK1*, *DLX2*, *DLX5*, and *EMX2*. Interestingly, PDX1 OE led to an upregulation of *BMP4* and *ERG2* (Supplementary Fig. S5C, D).

#### Inhibition of BMP and WNT signaling pathways in FOXA2-deficient pancreatic progenitor cells

Since FOXA2 deficiency led to a significant upregulation in the WNT and BMP signaling pathways, we thought to analyze whether inhibiting the BMP and WNT pathways are able to counteract the deleterious effects in the generation of PP2. We treated the cells with the WNT inhibitor, XAV939, for 4 days during stage 4 of differentiation (Supplementary Fig. S6A). We noticed that WNT inhibition led to a significant downregulation in the genes that were upregulated in the PP2 derived from  $FOXA2^{+/-}$  iPSCs and  $FOXA2^{-/-}$  iPSCs (Supplementary Fig. S6B). Also, WNT inhibition led to a significant increase in the expression of some genes that were







**Fig. 8 FOXA2 overexpression in PP2 reverse the phenotype of FOXA2 deficiency.** **A** Representative western blotting showing the overexpression of FOXA2 in the PP2 derived from FOXA2<sup>+/+</sup> iPSCs, and FOXA2<sup>-/-</sup> iPSCs, 48 h after transfection with FOXA2 plasmid or empty vector (EV). **B** Real-time PCR analysis for the expression of *PDX1*, *NKX6.1*, *SOX9*, *GATA6*, *PAX4*, *PTF1a*, *AMYLASE*, *TCF7L2*, *INSR*, *NOTCH*, *HES1*, *MNX1*, *ISL1*, *PROX1*, *PTPRN1*, *ADRA2A*, and *CDX2* in PP2 derived from FOXA2<sup>+/+</sup> iPSCs and FOXA2<sup>-/-</sup> iPSCs 48 h after transfection. **C** Real-time PCR analysis for the expression of *BMP4*, *NOG*, *MSX1*, *MSX2*, *DKK1*, *DLX2*, *DLX5*, *EMX2*, *ERG2*, *OTX1*, *OTX2*, and *RFX6* in PP2 derived from FOXA2<sup>+/+</sup> iPSCs and FOXA2<sup>-/-</sup> iPSCs 48 h after transfection. **D** Real-time PCR analysis for the expression of *INS*, *GCG*, *SST*, *PDX1*, *NKX6.1*, *ABCC8*, *KCNJ11*, *HHEX*, and *NEUROD1* in stage 7 derived from FOXA2<sup>+/+</sup> iPSCs and FOXA2<sup>-/-</sup> iPSCs transfected with FOXA2 plasmid or EV at stage 4. **E** Representative immunofluorescence images showing the expression of INS and GCG in stage 7 derived from FOXA2<sup>+/+</sup> iPSCs and FOXA2<sup>-/-</sup> iPSCs transfected with FOXA2 plasmid or EV at stage 4. **F** C-PEPTIDE (C-PEP) secretion (% of content) after stimulation with or without 30 mM KCl in the presence of low glucose (LG) in FOXA2<sup>+/+</sup> iPSC-derived beta cells transfected with FOXA2 plasmid or EV at stage 4. The data are presented as mean ± SD. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.



downregulated in the PP2 derived from *FOXA2*<sup>+/-</sup> iPSCs and *FOXA2*<sup>-/-</sup> iPSCs, particularly *NEUROD1*, *PAX4*, *TCF7L2*, *NOTCH*, *HES1*, *MNX1*, *PROX1*, and *PTPRN1* (Supplementary Fig. S6C). This indicates that inhibition of the WNT pathway, at least, partially reversed the phenotype noticed in the *FOXA2*-deficient PP2 stage (Supplementary Fig. S6A–C).

In the current protocol, we used BMP inhibitor, NOGGIN, during stages 2, 3, and 4 of differentiation. Therefore, to test the effect of BMP inhibition dose on the PP2 phenotype, we modified the protocol by treating stage 4 cells derived from *FOXA2*<sup>+/-</sup> iPSCs and *FOXA2*<sup>-/-</sup> iPSCs with two different concentrations of NOGGIN, 100 and 50 ng/mL (Supplementary Fig. S6D). The high concentration of NOGGIN (100 ng/mL) resulted in a significant reduction in the BMP pathway and other genes that were upregulated in the *FOXA2*-deficient PP2 in comparison to those treated with 50 ng/mL (Supplementary Fig. S6E). Although the high concentration of NOGGIN increased the expression of PP2 markers, these increases were not significant for most of the genes examined and showed some variations between PP2 derived from *FOXA2*<sup>+/-</sup> iPSCs and those derived from *FOXA2*<sup>-/-</sup> iPSCs (Supplementary Fig. S6F).

## Discussion

The role of *FOXA2* in pancreatic development has been studied in mouse models; however, the mechanism by which *FOXA2* defects contribute to the pathogenesis of human diseases is still not well-known due to the lack of the appropriate model that can mimic human phenotypes. In the current study, we established a human iPSC model to gain insight into the role of *FOXA2* during human pancreatic islet development and investigated the effect of *FOXA2* haploinsufficiency on pancreatic beta-cell differentiation in vitro. Our results showed that *FOXA2* is critical for the pancreatic endocrine specification. Taken together with the recent findings from other groups<sup>18,23</sup>, we suggest that *FOXA2* defects may lead to monogenic diabetes with other abnormalities.

In the current study, *FOXA2* haploinsufficiency led to a significant reduction in the expression of the key DE-specific TFs and retained the pluripotency markers in the iPSC-derived DE. This result disagrees with the recent findings obtained from *FOXA2*<sup>-/-</sup> hESCs, which showed that the DE and FG differentiation have not been affected by a complete loss of the *FOXA2* gene<sup>23</sup>. However, our results are in agreement with a recent study that demonstrated that *FOXA2* is a master regulator of endoderm formation and its absence in ESCs impairs the endoderm differentiation with improper activation of DE genes and sustained pluripotency markers<sup>31</sup>. Taken together, these data suggest a crucial role for *FOXA2* during DE formation in human.

Our results obtained from the PP2 and EPs stages showed that *FOXA2* haploinsufficiency led to a significant reduction in the expression of the monogenic diabetes-associated genes, such as *PDX1*, *HNF4A*, *HNF1A*, *NEUROD1*, *NGN3*, *PAX4*, *ABCC8*, *KCNJ11*, *GATA6*, and *MNX1*. In addition, several key pancreatic development-specific TFs were significantly downregulated in PP2 and EPs derived from *FOXA2*<sup>+/-</sup> iPSCs, such as *NKX6.1*, *NKX6.2*, *SOX9*, *NKX2.2*, *ISL1*, and *GATA6*, among others. Consistent with our findings, in mouse, *Foxa2* has been found to control the expression of the majority of those TFs, including *Pdx1*, *Nkx6.1*, *Nkx2.2*, *Hnf1a*, *Hnf4a*, *Kcnj11*, and *Abcc8*<sup>19,32</sup>. Furthermore, a recent study reported a significant reduction in the number of *PDX1*<sup>+</sup> pancreatic progenitors derived from *FOXA2*<sup>-/-</sup> hESCs<sup>23</sup>. Given the important role of *PDX1* in regulating the expression of several genes that are critical for pancreatic development and endocrine specification<sup>33,34</sup> and the fact that *PDX1* is the downstream target of *FOXA2*<sup>30</sup>, our results suggest that the effect of *FOXA2* on *PDX1* at the PP2 stage is one of the key mechanisms by which *FOXA2* control pancreatic endocrine development. In addition, at the PP2 stage, *FOXA2* haploinsufficiency resulted in a significant reduction in the NOTCH signaling pathway, which is important for early pancreatic development by enhancing PP2 expansion. Notch1 is expressed in the mouse pancreatic progenitors and activates the downstream target genes, *Hes1* and *Hey1*<sup>35,36</sup>. Interestingly, we observed that *NOTCH1*, *HES1*, and *HEY1* were significantly downregulated at the PP2 stage as a result of *FOXA2* deficiency. Although early studies showed that Notch inactivation enhances *Ngn3* and activates premature endocrine pancreatic differentiation<sup>37</sup>, recent studies reported that Notch is required for pancreatic endocrine specification by activating the expression of *Nkx6.1* and *Ngn3* activator, *Sox9*<sup>38,39</sup>. Consistent with these findings, in addition to NOTCH pathway inhibition, we noticed downregulation of endocrine-specific TFs, such as *SOX9*, *NKX6.1*, *NGN3*, *NKX2.2*, *NEUROD1*, and *PAX4* as a result of *FOXA2* deficiency.

Furthermore, our results demonstrated that *FOXA2* haploinsufficiency resulted in significant upregulation in the genes related to WNT and BMP signaling pathways at PP2 and EPs. Considering that WNT inhibition is crucial for endocrine development<sup>40</sup> and BMP signaling inhibition is required for *PDX1* induction in pancreatic progenitors<sup>41</sup>, we anticipate that increased both pathways are associated with the suppression of the pancreatic differentiation due to *FOXA2* haploinsufficiency. Confirming this concept, we demonstrated that inhibition of WNT or BMP pathways during the PP2 stage partially rescued the phenotype associated with *FOXA2* deficiency. The complete absence of *FOXA2* had a more marked effect on beta-cell differentiation, particularly after the PP2 stage.



FOXA2<sup>-/-</sup> iPSCs showed severe impairment in generating INS<sup>+</sup> and GCG<sup>+</sup> cells. These findings indicate that the severity of the phenotypes is associated with the dosage of FOXA2 expression. Transient FOXA2 OE in PP2 derived from FOXA2<sup>+/-</sup> iPSCs and FOXA2<sup>-/-</sup> iPSCs significantly upregulated the key pancreatic development-specific genes at PP2 and beta-cell stages and significantly downregulated the expression of WNT and BMP genes, indicating that the re-introduction of FOXA2 could reverse the phenotype associated with FOXA2 deficiency. Given the important roles of the downregulated and upregulated genes in controlling pancreatic endocrine development and beta-cell functionality, our findings indicate the important role of FOXA2 during pancreatic development and suggest that the patient with FOXA2 haploinsufficiency may develop diabetes later in life.

RNA-Seq and qPCR analyses showed that the top upregulated genes were associated with neurogenesis and nervous system development, which could be reversed after FOXA2 OE. This result is in agreement with the previous study that showed the activation of neuronal genes in the pancreatic islet of *Foxa2*-deficient mice<sup>11</sup>. Taken together, these findings suggest an important role for FOXA2 in suppressing neuronal fate during pancreatic differentiation to enhance the beta-cell program.

Although FOXA2 haploinsufficiency led to significant downregulation in the genes related to pancreatic endocrine development, it appears that the expression levels of those genes were still sufficient to generate functional, glucose-responsive beta cells at stage 7. In mice, *Foxa2* haploinsufficiency is enough for normal islet development; however, the deletion of both *Foxa1* and *Foxa2* in the mouse pancreas leads to pancreatic hypoplasia as a result of a *Pdx1* suppression<sup>10</sup>, indicating that *Foxa1* can compensate for the absence of *Foxa2* in rodents<sup>10</sup>. In this study, we found that FOXA1 expression was significantly downregulated in PP2 and EPs derived from FOXA2<sup>+/-</sup> iPSCs. Consistent with our findings, Lee et al. reported the reduction of FOXA1 in the DE and FG derived from FOXA2<sup>-/-</sup> hESCs<sup>23</sup>. These findings indicate that FOXA1 does not compensate for FOXA2 deficiency, at least, during the early stages of pancreatic development in human, highlighting the physiological differences between mouse and human.

In addition to the significant reduction of INS expression, GCG was significantly downregulated as a result of FOXA2 haploinsufficiency. Confirming the effect of FOXA2 deficiency on GCG expression, iPSCs lacking FOXA2 generated a very small number of GCG<sup>+</sup> cells at stage 7. Previous mouse studies showed that *Foxa2* activates the expression of *Gcg* and maintain the alpha cells by transcriptional regulation of *MafB*, *Kir6.2*, *Isl1*, and *Nkx2.2*<sup>20,42,43</sup>. In agreement with these findings, we found that all the endocrine-specific TFs were significantly

downregulated as a result of FOXA2 deficiency. These findings indicate that FOXA2 may also be involved in alpha cell development and regulates GCG expression in human pancreatic islet.

Whether the defect in FOXA2 leads to hypo- or hyperglycemia is still controversial. Recent reports have identified two young patients (2 and 5 years old) with hypoglycemic hyperinsulinemic phenotype due to two different FOXA2 mutations<sup>15,16</sup>. However, a more recent study identified a patient with diabetes due to another FOXA2 mutation<sup>18</sup>. Of note, these hypo- and hyperglycemic patients shared common features, such as growth hormone deficiency, hypopituitarism, and early hypoglycemia<sup>18</sup>. The hypoglycemic episode followed by hyperglycemia during childhood due to FOXA2 mutations is similar to some MODY gene mutations such as ABCC8<sup>44</sup>, HNF1A<sup>45</sup>, and HNF4A<sup>46</sup>. The link between FOXA2 defect and diabetes development has been reported in another human genomic study, in which an association of T2D risk alleles with FOXA2-bound enhancers has been found<sup>17</sup>. Taken together, our work supports the concept suggested that FOXA2 defects may lead to hypoglycemia at the early stage of life followed by hyperglycemia during late childhood or at a later stage<sup>18</sup>. Stekelenburg et al.<sup>18</sup> explained the possible mechanism of an early hypoglycemic episode associated with FOXA2 defects as a result of growth hormone deficiency<sup>16</sup> or the reduction in hepatic gluconeogenesis associated with the downregulation in the GCG expression<sup>18</sup>. Further clinical and experimental studies are needed to understand how FOXA2 defects influence glucose homeostasis and pancreatic islet functionality over time in human.

In conclusion, our current study provides the first human iPSC model for FOXA2 haploinsufficiency carrying the genetic information of the patient. Our results indicate that FOXA2 haploinsufficiency negatively impacted endocrine islet development by downregulating key TFs associated with islet cell development and upregulating genes associated with neuronal development and WNT and BMP pathways. Taken together with other recent reports<sup>17,18,23</sup>, our findings suggest that FOXA2 defects may lead to monogenic diabetes based on the gene dosage. However, it will be of interest to perform further studies to investigate how FOXA2 works with other TFs to maintain normal pancreatic endocrine development in human.

## Materials and methods

### Study approval

The protocols to obtain blood samples were approved by the Institutional Review Board (IRB) of Sidra Medicine (no. 1702007608) and QBRI/HBKU (no. 2018-002). Informed consent forms were signed by human subjects.

### Generation of iPSCs and their differentiation into pancreatic beta cells

iPSCs were generated from a patient with *FOXA2* heterozygous deletion (QBRI009-A; *FOXA2*<sup>+/-</sup> iPSCs) and healthy controls (Ctr1-iPSCs and Ctr2-iPSCs) as we previously reported<sup>24,25</sup>. All lines were extensively characterized as previously reported<sup>24,25</sup>. The first four stages of the pancreatic differentiation were performed using our protocol<sup>27</sup> and for further differentiation to beta cells, Reznia et al.<sup>28</sup> protocol was used (Supplementary Fig. S3A and Supplementary Table S1).

For WNT signaling inhibition, the cells were treated with the WNT inhibitor, 5  $\mu$ M XAV939 (Toric Bioscience, 3748) for 4 days during stage 4 and the control cells were treated with DMSO. For BMP inhibition, the cells were treated every day during stage 4 with 100 ng/mL NOGGIN, while the control cells were treated with 50 ng/mL of NOGGIN. The cells were collected at end of stage 4 to examine the effect of WNT and BMP inhibition on the dysregulated genes associated with *FOXA2* deficiency.

### Immunocytochemistry, flow cytometry, RT-PCR, and qPCR

Immunostaining and flow cytometry were performed as previously reported<sup>27,29</sup>. RT-PCR and qPCR were performed as previously reported<sup>25</sup>. (The antibody and primer details are listed in protocol was used in Supplementary Tables S2 and S3.)

### Western blot analysis

Total protein was extracted using RIPA buffer and separated by SDS-PAGE. The PVDF membranes were blocked with 10% skim milk in 0.5% TBST, incubated with primary antibodies overnight at 4 °C, and incubated with secondary antibodies at room temperature (protocol was used Supplementary Table S2). The membranes were incubated in SuperSignal West Pico Chemiluminescent substrate (Pierce, Loughborough, UK) detection reagent (VWR) and visualized using the iBright™ CL 1000 Imaging System (Invitrogen).

### RNA-sequencing analysis

The RNA-Sequencing (RNA-Seq) experiments and data analysis were performed as we previously reported<sup>25,47</sup>. For the analysis, the RNA-Seq data were pooled from two Ctr-iPSC lines and three *FOXA2*<sup>+/-</sup> iPSC lines of two independent experiments.

### CRISPR/Cas9-mediated generation of FOXA2-KO iPSCs

We generated two *FOXA2* iPSC lines from two control iPSC lines (Ctr1 and Ctr2). The cells were transfected with a plasmid expressing spCas9 and gRNA (Addgene, 79144) using Lipofectamine Stem Transfection Reagent following the manufacturer's instructions (ThermoFisher

Scientific) (Supplementary Fig. S4 and Supplementary Table S8).

### Glucose-stimulated insulin secretion (GSIS)

Beta-cell aggregates were incubated with low (2.8 mM) and high (20 mM) glucose, which was repeated two times. In the end, the clusters were incubated in low glucose with 30 mM KCL to depolarize the cells and release their C-PEP (C-PEPTIDE) contents. The C-PEP concentration in the collected supernatants was measured using Human C-Peptide ELISA Kit (Abcam, ab178641). Each value of C-PEP level of low or high glucose condition was normalized to its own total content of C-PEP in each sample. The stimulation indices were determined through the ratio between the C-PEP level at high glucose concentration to its own basal level secretion at the two challenges.

### Overexpression of FOXA2 and PDX1

At the end of day 2 of stage 4, the cells were dissociated with TrypLE and resuspended in the differentiation medium with 10  $\mu$ M Y-27632. The resuspended cells were either transfected with *FOXA2* plasmid (clone HsCD00330288 in pLenti6.2/v5-DEST; DNASU Plasmid Repository, Arizona State University, Tempe, AZ), *PDX1* plasmid (pLenti-GIII-CMV-RFP-2A-Puro, LV259702, abm), or the empty vectors. Transfection was carried out using the Lipofectamine™ 3000 Transfection Reagent following the manufacturer's instruction (ThermoFisher, L3000015). At 48 h post-transfection (end of stage 4), the cells were harvested for RNA and protein extraction. Some experiments were continued until the end of stage 7 (beta-cell stage) for further analyses.

### Statistical analysis

At least three biological replicates were used in most of the experiments and statistical analysis was carried out using unpaired two-tailed Student's *t*-test by Prism 8.

### Acknowledgements

We thank Ms. Bushra Memon (QBRI/HBKU) for helping in iPSC characterization. Also, we thank Dr. Gerald Pfister (QBRI/HBKU) for technical assistance in cell sorting and the Genomic Core (QBRI/HBKU) for technical support in RNA-sequencing. This work was funded by grants from Qatar Biomedical Research Institute (QBRI)/HBKU (Grant No. IGP 2014009; IGP 2016001) and from Qatar National Research Fund (QNRF) (Grant No. NPRP9-283-3-056).

### Author details

<sup>1</sup>Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar. <sup>2</sup>Biological Sciences Program, Carnegie Mellon University, Qatar Foundation, Education City, Doha, Qatar. <sup>3</sup>Division of Endocrinology, Department of Pediatric Medicine, Sidra Medicine, Doha, Qatar. <sup>4</sup>College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation, Education City, Doha, Qatar

**Author contributions**

E.M.A. conceived and designed the study and obtained research funding. A.K.E. performed the experiments. A.K.E. and E.M.A. analyzed and interpreted the data and wrote the manuscript. I.Y. analyzed the RNA-Seq data. G.A. participated in some experiments. K.H. contributed to sample and clinical data collection. All authors reviewed and approved the final version of the manuscript.

**Funding**

Open access funding provided by the Qatar National Library.

**Data availability**

The RNA-Seq data sets generated in the current study are available on the Zenodo repository at <https://zenodo.org/record/4362011#.X98RVCORrAI>

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Ethical statement**

The study has been approved by the appropriate institutional research ethics committee and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Informed consent**

Informed consent was obtained from all individual participants included in the study.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** The online version contains supplementary material available at (<https://doi.org/10.1038/s41419-021-03390-8>).

Received: 29 June 2020 Revised: 27 December 2020 Accepted: 29 December 2020

Published online: 20 January 2021

**References**

- Al-Khawaga, S. et al. Pathways governing development of stem cell-derived pancreatic beta cells: lessons from embryogenesis. *Biol. Rev. Camb. Philos. Soc.* **93**, 364–389 (2018).
- Pan, F. C. & Wright, C. Pancreas organogenesis: from bud to plexus to gland. *Dev. Dyn.* **240**, 530–565 (2011).
- Murphy, R., Ellard, S. & Hattersley, A. T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. *Nat. Clin. Pr. Endocrinol. Metab.* **4**, 200–213 (2008).
- De Franco, E. From biology to genes and back again: gene discovery for monogenic forms of beta-cell dysfunction in diabetes. *J. Mol. Biol.* **432**, 1535–1550 (2020).
- Friedman, J. R. & Kaestner, K. H. The Foxa family of transcription factors in development and metabolism. *Cell Mol. Life Sci.* **63**, 2317–2328 (2006).
- Kaestner, K. H., Hiemisch, H. & Schutz, G. Targeted disruption of the gene encoding hepatocyte nuclear factor 3gamma results in reduced transcription of hepatocyte-specific genes. *Mol. Cell Biol.* **18**, 4245–4251 (1998).
- Weinstein, D. C. et al. The winged-helix transcription factor HNF-3 beta is required for notochord development in the mouse embryo. *Cell* **78**, 575–588 (1994).
- Ang, S. L. & Rossant, J. HNF-3 beta is essential for node and notochord formation in mouse development. *Cell* **78**, 561–574 (1994).
- Willmann, S. J. et al. The global gene expression profile of the secondary transition during pancreatic development. *Mech. Dev.* **139**, 51–64 (2016).
- Gao, N. et al. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev.* **22**, 3435–3448 (2008).
- Gao, N. et al. Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell. *Mol. Endocrinol.* **24**, 1594–1604 (2010).
- Lee, C. S. et al. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. *Diabetes* **51**, 2546–2551 (2002).
- Sund, N. J. et al. Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. *Genes Dev.* **15**, 1706–1715 (2001).
- Dines, J. N. et al. Expanding phenotype with severe midline brain anomalies and missense variant supports a causal role for FOXA2 in 20p11.2 deletion syndrome. *Am. J. Med. Genet. A* **179**, 1783–1790 (2019).
- Giri, D. et al. Novel FOXA2 mutation causes hyperinsulinism, hypopituitarism with craniofacial and endoderm-derived organ abnormalities. *Hum. Mol. Genet.* **26**, 4315–4326 (2017).
- Vajravelu, M. E. et al. Congenital hyperinsulinism and hypopituitarism attributable to a mutation in FOXA2. *J. Clin. Endocrinol. Metab.* **103**, 1042–1047 (2018).
- Gaulton, K. J. et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. *Nat. Genet.* **47**, 1415–1425 (2015).
- Stekelenburg, C. et al. Exome sequencing identifies a de novo FOXA2 variant in a patient with syndromic diabetes. *Pediatr. Diabetes* **20**, 366–369 (2019).
- Bastidas-Ponce, A. et al. Foxa2 and Pdx1 cooperatively regulate postnatal maturation of pancreatic beta-cells. *Mol. Metab.* **6**, 524–534 (2017).
- Heddad Masson, M. et al. Foxa1 and Foxa2 regulate alpha-cell differentiation, glucagon biosynthesis, and secretion. *Endocrinology* **155**, 3781–3792 (2014).
- Lantz, K. A. et al. Foxa2 regulates multiple pathways of insulin secretion. *J. Clin. Invest.* **114**, 512–520 (2004).
- Abdelalim, E. M. Modeling different types of diabetes using human pluripotent stem cells. *Cell Mol. Life Sci.* <https://doi.org/10.1007/s00018-020-03710-9> (2020).
- Lee, K. et al. FOXA2 is required for enhancer priming during pancreatic differentiation. *Cell Rep.* **28**, 382–393.e387 (2019).
- Elsayed, A. K. et al. Generation of a human induced pluripotent stem cell line (QBRII009-A) from a patient with a heterozygous deletion of FOXA2. *Stem Cell Res.* **42**, 101705 (2020).
- Ali, G. et al. Keratinocytes derived from patient-specific induced pluripotent stem cells recapitulate the genetic signature of psoriasis disease. *Stem Cells Dev.* **29**, 383–400 (2020).
- Mohammed, I. et al. Haploinsufficiency of the FOXA2 associated with a complex clinical phenotype. *Mol. Genet. Genomic Med.* **8**, e1086 (2020).
- Memon, B., Karam, M., Al-Khawaga, S. & Abdelalim, E. M. Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1. *Stem Cell Res. Ther.* **9**, 15 (2018).
- Rezania, A. et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat. Biotechnol.* **32**, 1121–1133 (2014).
- Aigha, I. I., Memon, B., Elsayed, A. K. & Abdelalim, E. M. Differentiation of human pluripotent stem cells into two distinct NKX6.1 populations of pancreatic progenitors. *Stem Cell Res. Ther.* **9**, 83 (2018).
- Ben-Shushan, E., Marshak, S., Shoshkes, M., Cerasi, E. & Melloul, D. A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta (HNF-3beta), HNF-1alpha, and SPs transcription factors. *J. Biol. Chem.* **276**, 17533–17540 (2001).
- Cernilogar, F. M. et al. Pre-marked chromatin and transcription factor co-binding shape the pioneering activity of Foxa2. *Nucleic Acids Res.* **47**, 9069–9086 (2019).
- Wang, H., Gauthier, B. R., Hagenfeldt-Johansson, K. A., Iezzi, M. & Wollheim, C. B. Foxa2 (HNF3beta) controls multiple genes implicated in metabolism-secretion coupling of glucose-induced insulin release. *J. Biol. Chem.* **277**, 17564–17570 (2002).
- Gao, T. et al. Pdx1 maintains beta cell identity and function by repressing an alpha cell program. *Cell Metab.* **19**, 259–271 (2014).
- Bernardo, A. S. et al. Biphasic induction of Pdx1 in mouse and human embryonic stem cells can mimic development of pancreatic beta-cells. *Stem Cells* **27**, 341–351 (2009).
- Lammert, E., Brown, J. & Melton, D. A. Notch gene expression during pancreatic organogenesis. *Mech. Dev.* **94**, 199–203 (2000).
- Rooman, I. et al. Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. *Am. J. Pathol.* **169**, 1206–1214 (2006).
- Li, X. Y., Zhai, W. J. & Teng, C. B. Notch signaling in pancreatic development. *Int. J. Mol. Sci.* **17**, 48 (2015).



38. Afelik, S. et al. Notch-mediated patterning and cell fate allocation of pancreatic progenitor cells. *Development* **139**, 1744–1753 (2012).
39. Shih, H. P. et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. *Development* **139**, 2488–2499 (2012).
40. Sharon, N. et al. Wnt signaling separates the progenitor and endocrine compartments during pancreas development. *Cell Rep.* **27**, 2281–2291 e2285 (2019).
41. Tan, M., Jiang, L., Li, Y. & Jiang, W. Dual inhibition of BMP and WNT signals promotes pancreatic differentiation from human pluripotent stem cells. *Stem Cells Int.* **2019**, 5026793 (2019).
42. Gauthier, B. R. et al. Hepatic nuclear factor-3 (HNF-3 or Foxa2) regulates glucagon gene transcription by binding to the G1 and G2 promoter elements. *Mol. Endocrinol.* **16**, 170–183 (2002).
43. Gosmain, Y., Avril, I., Mamin, A. & Philippe, J. Pax-6 and c-Maf functionally interact with the alpha-cell-specific DNA element G1 in vivo to promote glucagon gene expression. *J. Biol. Chem.* **282**, 35024–35034 (2007).
44. Huopio, H. et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. *J. Clin. Invest.* **106**, 897–906 (2000).
45. Dusatkova, P. et al. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. *J. Pediatr. Endocrinol. Metab.* **24**, 187–189 (2011).
46. Kapoor, R. R. et al. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. *Diabetes* **57**, 1659–1663 (2008).
47. Karam, M., Younis, I., Elareer, N. R., Nasser, S. & Abdelalim, E. M. Scalable generation of mesenchymal stem cells and adipocytes from human pluripotent stem cells. *Cells* **9**, 710 (2020).